Champions Oncology, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended October 31, 2014; comparisons are with the corresponding 2013 periods. Unless noted otherwise, amounts are in U.S. dollars in thousands. The company develops and sells oncology solutions using its TumorGraft platform through Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS).
Financial performance
| Metric | Three months ended Oct. 31, 2014 | Six months ended Oct. 31, 2014 | Comparable 2013 period |
|---|---|---|---|
| Revenue | $1,882 | $3,793 | $2,383 quarter; $5,403 six months |
| Operating loss | $(3,666) | $(7,387) | $(1,701) quarter; $(2,472) six months |
| Net loss | $(3,078) | $(6,684) | $(2,318) quarter; $(4,556) six months |
| Basic loss per share | $(0.05) | $(0.10) | $(0.03) quarter; $(0.07) six months |
- Quarterly revenue comprised POS $452 and TOS $1,430; six-month revenue comprised POS $792 and TOS $3,001.
- Quarterly POS gross margin was negative 67.9% and TOS gross margin was 32.9%. For the six months, POS gross margin was negative 91.4% and TOS gross margin was 35.9%.
- Six-month operating cash use was $5,247, compared with $1,902 in 2013. Investing cash use was $71; financing provided $2. Cash declined $5,316 to $575.
- At October 31, cash and cash equivalents were $575, current assets $2,083, current liabilities $3,938, and working capital was negative approximately $1.8 million. Total liabilities were $5,169; stockholders’ deficit was $1,858. The balance sheet showed a $1,231 warrant liability; the filing reports no conventional borrowings at October 31.
- Six-month stock-based compensation was $1,627. A $780 noncash gain from the change in fair value of warrant liabilities reduced reported losses; the warrant liability is valued using Level 3 inputs.
Material changes versus 2013
- Revenue fell 21.0% for the quarter and 29.8% for the six-month period. POS revenue declined 27.4% and 36.4%, respectively; TOS revenue declined 18.8% and 27.8%.
- Management attributed the POS decline to lower implant revenue, discounts used to acquire strategic tumors for the TumorBank, and fewer tests per panel. TOS revenue was affected by longer conversion time from ongoing studies to recognized revenue.
- Six-month research and development expense rose 146.8% to $2,663, primarily reflecting increased TumorBank characterization investment. Sales and marketing expense rose 67.6% to $2,246, reflecting expansion of the TOS business development team. G&A rose 20.2% to $2,831, partly due to compensation and stock compensation associated with expansion.
- Operating losses widened as revenue declined while expenses increased. POS and TOS segment losses for the six months were $1,583 and $2,400, respectively; TOS had reported segment profit of $1,069 in the prior-year period.
Outlook, liquidity, and risks
- Management said the $575 cash balance at October 31 was expected to fund operations only through at least December 15, 2014. On December 1, the CEO and President each purchased a $1 million convertible promissory note. The notes bear 12% interest and mature in 90 days; conversion is at the noteholders’ option. Management said proceeds, if converted at maturity, together with existing cash would fund operations through at least March 31, 2015.
- If the notes are not converted, the company said it may lack cash to repay them and could default. It needs additional external capital to continue beyond the applicable runway; financing may be unavailable or on unacceptable terms. Equity financing could dilute shareholders, while debt could impose payment obligations and covenants.
- The company expects operating losses until it can generate significantly more revenue. If it cannot raise capital, it may have to reduce, delay, or eliminate R&D and other activities. No specific revenue, earnings, or cash-flow guidance was provided.
- Warrants issued in private placements include exercise-price reset provisions and are recorded as a liability. Registration-rights penalties could range from $50,000 to $130,000 per 30-day default period, subject to an aggregate cap; the company did not consider payment probable and recorded no accrual. The filing reports no known legal proceedings.
- Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting during the period.
Important facts for investors to verify
- Whether the $2 million insider notes were converted, repaid, or refinanced at maturity, and what financing supports ongoing operations.
- Actual cash burn and liquidity after October 31, including whether the stated operating runway was achieved.
- Whether POS and TOS revenue declines and weak POS margins improve, and whether TOS study activity converts to recognized revenue.
- Potential dilution from note conversion, the substantial outstanding options and warrants, and future capital raises.
- Warrant-liability valuation movements and any registration-default penalties or other material contingencies.